OWC Pharmaceutical Research Corp. to Report Top Line Results (TLR) for a Safety Study on Its Cannabis-based Tablets

Monday, October 7, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

RAMAT GAN, Israel, Oct. 7, 2019 /PRNewswire/ -- OWC Pharmaceutical Research Corp. (OTCQB: OWCP), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, announced today that, on September 25, 2019, One World Cannabis Ltd., a company organized and existing

under the laws of Israel and a wholly-owned subsidiary of OWC received Top Line Results (TLR) of its single-dose, randomized, crossover study to compare the safety, tolerability and pharmacokinetics (PK) of OWC's Medical Grade Cannabis - Orally Disintegrating Tablets (MGC-ODT) vs. buccal Sativex®, in healthy adult volunteers. The study was conducted at the Sourasky Medical Center in Tel Aviv. In this study, participants were administered randomly, either Sativex (5.4 mg THC, 5.0 mg CBD) or OWC-ODT (4.2 mg THC, 5 mg CBD), and then crossed over, with a minimum interval of two weeks. Plasma was collected in the 24 hours following drug administration, at pre-determined time points, and side effects were monitored. The concentrations of THC, CBD and 11-OH-THC were quantified, and their plasma PK determined.

The TLR show that both MGC-ODT and Sativex® administration had comparable mean times of peak concentration, half-life and elimination rates for each of the three analytes (THC, THC metabolite 11-hydroxy-THC and CBD). The results indicated dose-related comparability of both products in rate of absorption and bioavailability. The incidence of treatment related adverse events (AEs) were similar between the treatments.

The most common treatment related AEs were hunger (reported in 25% of subjects treated with MGC-ODT), thirst (reported in 18.75% and 6.25% of subjects treated with MGC-ODT and Sativex®, respectively), dizziness (reported in 18.75% and 18.75% of subjects treated with MGC-ODT and Sativex®, respectively), dysgeusia (reported in 12.5% and 25% of subjects treated with MGC-ODT and Sativex®, respectively). Administration of MGC-ODT was judged to be well tolerated and no unexpected safety signals were observed.

Top Line Results Conclusions: OWC- Orally Disintegrating Tablet is safe to use and appears to have similar PK and bioavailability as Sativex®. Therefore, OWC intends to apply to the Israel Ministry of Health to obtain necessary approvals to market its Medical Grade Cannabis - Orally Disintegrating Tablets in Israel.

About OWC Pharmaceutical Research Corp

OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One World Cannabis Ltd., (collectively 'OWC' or the 'Company') conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines.

OWCP is also developing unique and effective delivery systems and dosage forms of medical cannabis. All OWC research is conducted at leading Israeli hospitals and scientific institutions and led by internationally renowned investigators.

Contacts: Mordechai BignitzChief Executive Officer OWC Pharmaceutical Research Corp.info@owcpharma.comTel: +972-(72)-260-8004


Cision View original content:http://www.prnewswire.com/news-releases/owc-pharmaceutical-research-corp-to-report-top-line-results-tlr-for-a-safety-study-on-its-cannabis-based-tablets-300933105.html

SOURCE OWC Pharmaceutical Research Corp.

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z



Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store